Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,343.72
(
-0.39%
)
US TECH 100
22,535.60
(
0.92%
)
Dow Jones
45,216.14
(
0.00%
)
Brent Oil
106.56
(
-1.85%
)
Bitcoin
66,576.50
(
-0.19%
)
News Focus
News Focus
Post# of 257314
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122824
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: io_io post# 18656

Wednesday, 11/16/2005 9:44:33 PM

Wednesday, November 16, 2005 9:44:33 PM

Post# of 257314
>RBC Markets analyst Jason Kantor upgraded Genitope to "Outperform" from "Sector Perform," on confidence that promising Phase II trial results will transfer to an ongoing late-stage, or Phase III, clinical trial for the company's MyVax personalized cancer vaccine.<

Consider the source—Kantor has had the hots for GENR the whole way down from $6+.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today